Reducing Liquid Biopsy Results to (Routine) Clinical Practice

Time: 1:30 pm
day: Day Two


• Liquid Biopsies have become the preferred sample type in treatment decisions formany cancer patients

• Interpretation of Liquid Biopsy results remain problematic for many technical and administrative reasons, delaying a more rapid uptake for clinical decision-making

• The early results reported here are from an FNIH Consortium to validate commercial ctDNA control material to FDA-requirement levels, enhancing confidence in ctDNA results